Background Patients with rheumatoid arthritis (RA) commonly use oral glucocorticoids (GCs)
and proton pump inhibitors (PPIs), both associated with osteoporotic fractures. We …

Objectives Clinical trials have shown that low-dose glucocorticoid therapy in patients with
RA reduces bone loss in hands or hip, but the effect on osteoporotic fractures is not yet clear …

Objective. To identify the effects of glucocorticoids (GC) on various types of fractures in
patients with rheumatoid arthritis (RA). Methods. We used the Korean National Healthcare …

Retrospective claims analysis indicated that high levels of daily and cumulative doses of
systemic glucocorticoids were associated with elevated fracture risk in a large cohort of new …

Objective The negative effects of glucocorticoids on bone depend on dose and treatment
duration. However, it is unclear whether a safe dose exists, especially for patients with …

Little data exist on the frequency of fracture among oral glucocorticoid users. We examined
the effect of oral glucocorticoids on fracture incidence using data from randomized controlled …

Objective The American College of Rheumatology (ACR) updated its guidelines on the
prevention and treatment of glucocorticoid‐induced osteoporosis (GIO) in 2010. An …

Objective To evaluate the risk of fracture in patients receiving intermittent therapy with high‐
dose oral glucocorticoids (GCs). Methods The study group comprised 191,752 patients from …

Osteoporosis and fractures are common and invalidating consequences of chronic
glucorticoid (GC) treatment. Reliable information regarding the epidemiology of GC induced …

Objective The objective is to update recommendations for prevention and treatment of
glucocorticoid‐induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic …